Century Therapeutics, Inc. (IPSC) News
Filter IPSC News Items
IPSC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest IPSC News From Around the Web
Below are the latest news stories about CENTURY THERAPEUTICS INC that investors may wish to consider to help them evaluate IPSC as an investment opportunity.
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare ConferencePHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that members of the management team will participate in the following events at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024: Autoimmune Disease Cell Therapy Panel: 3:00 PM ET Presenter: Chad Cowan, Ph.D., Chief |
What Makes Century Therapeutics (IPSC) a New Buy StockCentury Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Century Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsCentury Therapeutics ( NASDAQ:IPSC ) Third Quarter 2024 Results Key Financial Results Net loss: US$31.2m (loss narrowed... |
Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue EstimatesCentury Therapeutics (IPSC) delivered earnings and revenue surprises of 19.57% and 69.74%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates– Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy –– Overall response rate (ORR) of 83% observed at CNTY-101 Dose Level 3B alongside a favorable safety profile in patients with r/r B-cell lymphomas in Phase 1 ELiPSE-1 study –– CNTY-101 shows persistence upon repeated cell dosing at Dose Level 3B, consistent with the anticipated protective activity of Century’s proprietary Allo-Evasion™ tec |
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting– Company to share preclinical data across diverse pipeline of iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune disease (AID) – – Preclinical data on development of iPSC-derived CD4+ and CD8+ CAR T cells that demonstrate function comparable to primary αβ CAR-T cells, allowing for control of tumors in vivo without the need for exogenous or engineered cytokines – – Posters include demonstration of advances in gene editing and transgene design that enable greater control and |
Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation ConferencePHILADELPHIA, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that Brent Pfeiffenberger, Pharm.D., Chief Executive Officer, and Chad Cowan, Ph.D., Chief Scientific Officer, will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 9:30am ET. |
We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
electroCore (ECOR) Stock Jumps 11.7%: Will It Continue to Soar?electroCore (ECOR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer- Morgan Conn, Ph.D., seasoned biotech executive with expertise in financing, business development, and corporate strategy, appointed as Chief Financial Officer - - Chad Cowan, Ph.D., cell therapy pioneer, founder, and former CEO of Clade Therapeutics, appointed as Chief Scientific Officer - - Hy Levitsky, M.D., President of Research and Development, to transition to an advisor to Century - PHILADELPHIA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative |